NCT04560413 is a clinical trial in SARS-CoV-2, sponsored by Fatih Sultan Mehmet Training and Research Hospital.

Who is sponsoring NCT04560413?

NCT04560413 is sponsored by Fatih Sultan Mehmet Training and Research Hospital.

What condition does NCT04560413 study?

NCT04560413 studies SARS-CoV-2, Post-stroke Depression, Anxiety and Fear.

Is NCT04560413 still recruiting?

NCT04560413 is currently completed. Last updated 30 September 2020.

Last reviewed 2020-09-30 · How we verify

NCT04560413

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Depression, Anxiety and SARS-CoV-2 (Covid-19) Phobia in Post-stroke Patients

Completed Last updated 30 September 2020

What this trial tests

trial in SARS-CoV-2 in 77 participants. Completed in 10 August 2020.

Timeline

1 June 2020

Primary endpoint
25 July 2020

10 August 2020

Quick facts

Lead sponsor	Fatih Sultan Mehmet Training and Research Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	77
Start date	1 June 2020
Primary completion	25 July 2020
Estimated completion	10 August 2020
Sites	1 location across Turkey (Türkiye)

Conditions studied

SARS-CoV-2 — all drugs for SARS-CoV-2 →
Post-stroke Depression — all drugs for Post-stroke Depression →
Anxiety and Fear — all drugs for Anxiety and Fear →

Sponsor

Fatih Sultan Mehmet Training and Research Hospital

Who can join

18 and older, any sex, with SARS-CoV-2 or Post-stroke Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has begun, first in Wuhan, China, and then became a pandemic. The first SARS-CoV-2 case in Turkey was reported on March 11, 2020. People older than 65 years old became subject to lock down measures beginning on March 21, while people younger than 20 years old became subject to lock down measures beginning on April 03. A total lock down has been implemented a few times lasting between 3 to 4 days, especially at weekends. Several studies show that mental health problems could occur in public during the SARS-CoV-2 pandemic. Depression and anxiety are a commonly known mental health issue in post-stroke patients. This patient population, who usually have to spend most of their time at home, remained completely at home and socially isolated due to the precautions required by the pandemic. Based on the above research evidence; depression, anxiety and phobia of SARS-CoV-2 may increase in the post stroke patients due to being in risk group and effects of measures taken against SARS-CoV-2 pandemic. Therefore, we aimed to assess the depression, anxiety and SARS-CoV-2 phobia in post stroke patients during SARS-CoV-2 outbreak, and to explore the potential influence factors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Impact of Government Lockdowns on the Mental Health of the General Population: A Systematic Review and Meta-analysis.
Okazaki Y, Tsujimoto Y, Yamada K, Saka N, et al · · 2025 · PMID 40453305 · DOI 10.7759/cureus.83249

Verify or expand the search:

Other recruiting trials for SARS-CoV-2

Currently open trials in the same condition.

NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting
NCT06585241 — A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations · Phase 4 · recruiting
NCT05876377 — Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data · active not recruiting
NCT05799651 — Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults · Phase 1 · active not recruiting

Other Fatih Sultan Mehmet Training and Research Hospital trials

Trials by the same sponsor.

NCT07589582 — Active Noise-Cancelling Headphones Reduce Operative Time and Improve Procedural Consistency in ACL Reconstruction l · NA · active not recruiting
NCT07523828 — Laryngeal Edema Assessment by Cuff Leak Test and Ultrasound in ICU Patients and Its Relationship With Weaning Success · not yet recruiting
NCT07487038 — The Efficacy and Safety of a Single-Dose Hyaluronic Acid Injection in the Treatment of Knee Osteoarthritis · not yet recruiting
NCT07485465 — Lymphoedema Diagnosis and Treatment · not yet recruiting
NCT07451925 — Prediction of Postoperative Pain Using Venous Cannulation Pain and Preoperative Anxiety Scores · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04560413 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fatih Sultan Mehmet Training and Research Hospital
Last refreshed: 30 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04560413.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing